Siponimod, also known as BAF-312, is a a potent and orally selective S1P Receptor Modulator with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively. Development of sphingosine-1-phosphate receptor 1 (S1P1) modulators to dampen inflammation and its sequelae is becoming increasingly promising for treating medical conditions characterized by significant immunopathology.
Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Mi, Yuan; Fan, Yi; Wang, Xing; Tuntland, Tove; Che, Jianwei; Lefebvre, Sophie; Chen, Yu; Chu, Alan; Hinterding, Klaus; Gardin, Anne; End, Peter; Heining, Peter; Bruns, Christian; Cooke, Nigel G.; Nuesslein-Hildesheim, Barbara. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Medicinal Chemistry Letters. Volume 4. Issue 3. Pages 333-337. Journal; Online Computer File. (2013).
Zhang, Chengzhi; Chakma, Justin. Preparation of deuterium-substituted azetidine compounds as sphingosine 1-phosphate receptor. Assignee Auspex Pharmaceuticals, Inc., USA. WO 2017120124. (2017).
Gallou, Fabrice; Sedelmeier, Joerg Matthias; Vogel, Caspar. (Assignee: Novartis AG, Switz). Process for preparing N-(4-cyclohexyl-3-trifluoromethylbenzyloxy)acetimidic acid ethyl ester. WO 2013113915 (2013).
